Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis

Inclusion Criteria: * Clinical diagnosis of distal-lateral or lateral subungual onychomycosis of one great toenail (the target nail) without matrix involvement * Target nail plate showing between 25% and 60% of clinically infected area * Patient must have at least 2 mm of unaffected proximal target nail area * Target nail infection due exclusively to a dermatophyte (from positive fungal culture as reported by the central mycological laboratory) * Female patient of childbearing potential must use an efficient contraceptive method for at least 2 months prior to screening visit * Female patient of childbearing potential must have a negative urinary pregnancy test at the screening visit Exclusion Criteria: * Patient with more than 3 affected nails * Patient with onychomycosis with matrix involvement * Patient with psoriasis, lichen planus or other abnormalities that could result in clinically abnormal toenail(s) * Patient with moccasin-type tinea pedis * Patient who has received systemic antifungal therapy or any topical antifungal therapy applied to the toenails within 3 months prior to screening visit * Patient with known hypersensitivity to investigational products' ingredient(s) * Patient who is currently participating or who has participated in another clinical study within 4 weeks prior to screening visit